Long-term efficacy and safety of alemtuzumab in participants with highly active MS: TOPAZ clinical trial and interim analysis of TREAT-MS real-world study by Tjalf Ziemssen, Ann D. Bass, Bart Van Wijmeersch, Sara Eichau, Stephan Richter, Frank Hoffmann, Nicole M. Armstrong, Magdalena Chirieac, Janete Cunha-Santos, Barry A. Singer

“…Objectives: To examine long-term efficacy and safety of alemtuzumab in participants with multiple sclerosis (MS) and highly active disease (HAD) by combining up to 13 years of TOPAZ data and TREAT-MS interim data. …”
Get full text

Diving into Diagnostic Complexity: A Case Study of Spontaneous Hemothorax by Maryam Sarkhosh, Atiyeh Sadat Sajadi, Omid Moradi Moghaddam, Parisa Moradi Majd

“…A 29-year-old female with multiple sclerosis presented with severe chest symptoms, leading to pleural effusion requiring chest tube insertion. …”
Get full text

Historical Pathways for Opioid Addiction, Withdrawal with Traditional and Alternative Treatment Options with Ketamine, Cannabinoids, and Noribogaine: A Narrative Review by Amber N. Edinoff, Natalie W. Wu, Catherine A. Nix, Bryce Bonin, Rama Mouhaffel, Stephen Vining, William Gibson, Elyse M. Cornett, Kevin S. Murnane, Adam M. Kaye, Alan D. Kaye

“…These include, but are not limited to epilepsy, Parkinson's disease, multiple sclerosis, chronic pain conditions, anxiety disorders, and addiction. …”
Get full text

Deep learning-based prediction of autoimmune diseases by Donghong Yang, Xin Peng, Senlin Zheng, Shenglan Peng

“…In particular, the average area under the ROC curve (AUC) of the AutoY model exceeded 0.93 in the prediction of all the diseases, and the AUC value reached 0.99 in two diseases, type 1 diabetes and multiple sclerosis. These results demonstrate the high accuracy, stability, and good generalization ability of the two models, which makes them promising tools in the field of autoimmune disease prediction and provides support for the use of the TCR bank for the noninvasive detection of autoimmune disease non-invasive detection is supported.…”
Get full text

More than just a number: the gut microbiota and brain function across the extremes of life by Nathan D. Nuzum, Clara Deady, Sarah Kittel-Schneider, John F. Cryan, Siobhain M. O'Mahony, Gerard Clarke

“…Longitudinal interventions are being conducted in AD, PD, amyotrophic lateral sclerosis, Huntington's disease, and multiple sclerosis. Neurodevelopmental research has also seen a boon in microbiome-related clinical research including in autism, Attention-deficit/hyperactivity disorder, and schizophrenia, which is confirming prior animal model work regarding the key time-windows in the gut microbiome important for infant cognition. …”
Get full text

The impact of gut microbiome on neuro-autoimmune demyelinating diseases by Pouria Abolfazli, Cristina Nkene Apue Nchama, Brandon Lucke-Wold

“… Demyelinating diseases, including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and chronic inflammatory demyelinating polyneuropathy (CIDP), are characterized by dysregulated immune responses to self-antigens, leading to myelin loss. …”
Get full text

Removing limitations surrounding terpenoid biosynthesis by biotechnological techniques in Ferula sp.: A review by Zahra Aghaali, Jun-Li Yang, Mohammad Reza Naghavi, Meisam Zargar

“…Besides, a growing body of research proves the healing efficacy of Ferula plants in treating modern diseases, such as multiple sclerosis (MS), HIV, and COVID19. The major challenge surrounding the commercialization of Ferula-derived terpenoids is their low quantity in Ferula plants. …”
Get full text

Genetic evidence for the liver-brain axis: lipid metabolism and neurodegenerative disease risk by Zeyu Wang, Zixiao Yin, Guangyong Sun, Dong Zhang, Jianguo Zhang

“…A systematic investigation of the genetic relationship between lipid metabolism abnormalities and ND, namely, Alzheimer's disease (AD), Parkinson's disease (PD), multiple sclerosis (MS), and amyotrophic lateral sclerosis (ALS), is lacking. …”
Get full text

Smartphone postural sway and pronator drift tests as measures of neurological disability by Michael Calcagni, Peter Kosa, Bibi Bielekova

“…These tests capture different domains of postural control and motoric dysfunction in healthy volunteers (n = 13) and people with neurological disorders (n = 68 relapsing–remitting multiple sclerosis [MS]; n = 21 secondary progressive MS; n = 23 primary progressive MS; n = 13 other inflammatory neurological diseases; n = 21 non-inflammatory neurological diseases; n = 4 clinically isolated syndrome; n = 1 radiologically isolated syndrome). …”
Get full text

The sphingosine‐1‐phosphate signaling pathway (sphingosine‐1‐phosphate and its receptor, sphingosine kinase) and epilepsy by Lin Wang, Qingxia Kong, Xinyi Leng, Howan Leung, Yang Li

“…Fingolimod (FTY720) is the first S1P receptor modulator developed and approved for the treatment of multiple sclerosis. More and more studies have proven that the S1P signaling pathway is closely related to epilepsy, drug‐resistant epilepsy, epilepsy comorbidities, or other epilepsy‐causing diseases. …”
Get full text

Causal association between non-thyroidal autoimmune diseases and Graves' ophthalmopathy: A mendelian randomization study by Lan Ma, Xue Jiang, Zhijia Hou, Dongmei Li

“…Materials: Single nucleotide polymorphisms (SNPs) associated with inflammatory bowel disease (IBD), multiple sclerosis (MS), psoriasis vulgaris (PV), type 1 diabetes (T1D), systemic lupus erythematosus (SLE), and rheumatoid arthritis (RA) were obtained from the IEU Open genome-wide association studies (GWAS) database, GWAS data for GO were obtained from the FinnGen database. …”
Get full text

Multi-omic spatial effects on high-resolution AI-derived retinal thickness by V. E. Jackson, Y. Wu, R. Bonelli, J. P. Owen, L. W. Scott, S. Farashi, Y. Kihara, M. L. Gantner, C. Egan, K. M. Williams, B. R. E. Ansell, A. Tufail, A. Y. Lee, M. Bahlo

“…Analysis of common genomic variants, metabolomic, blood and immune biomarkers, disease PheCodes and genetic scores across a fine-scale macular thickness grid, reveals multiple novel genetic loci including four on the X chromosome; retinal thinning associated with many systemic disorders including multiple sclerosis; and multiple associations to correlated metabolites that cluster spatially in the retina. …”
Get full text

Dimethyl fumarate promotes the degradation of HNF1B and suppresses the progression of clear cell renal cell carcinoma by Yue Dai, Hongchen Li, Shiyin Fan, Kai Wang, Ziyi Cui, Xinyu Zhao, Xue Sun, Mingen Lin, Jiaxi Li, Yi Gao, Ziyin Tian, Hui Yang, Bingbing Zha, Lei Lv, Yanping Xu

“…Here, we demonstrate that dimethyl fumarate (DMF), an approved medication for multiple sclerosis [1] and psoriasis, can inhibit the proliferation of ccRCC cells. …”
Get full text

Cellular rejuvenation protects neurons from inflammation-mediated cell death by Sienna S. Drake, Abdulshakour Mohammadnia, Aliyah Zaman, Christine Gianfelice, Kali Heale, Adam M.R. Groh, Elizabeth M.-L. Hua, Matthew A. Hintermayer, Yuancheng Ryan Lu, David Gosselin, Stephanie Zandee, Alexandre Prat, Jo Anne Stratton, David A. Sinclair, Alyson E. Fournier

“…Summary: In multiple sclerosis (MS), inflammation of the central nervous system results in demyelination, neuroaxonal injury, and cell death. …”
Get full text

Multicentre case-control study on the association between COVID-19 vaccines and neurological disorders (COVIVAX) by Elisabetta Pupillo, Elisa Bianchi, Ettore Beghi, Francesco Andrea Pedrazzini, Angela Giglio, Edoardo Dalmato Schilke, Marco Percetti, Carlo Morotti Colleoni, Gabriele Mainini, Paolo Calabresi, Guido Primiano, Giovanni Frisullo, Alessandro Padovani, Viviana Cristillo, Andrea Pilotto, Davide Arici, Stefano Gipponi, Gioacchino Tedeschi, Alessandro d’Ambrosio, Rosario Domenico Melisi, Antonio Gallo, Alvino Bisecco, Andrea Salmaggi, Paola Basilico, Chiara Scaccabarozzi, Lorenzo Kiferle, Raffaella Valenti, Gianluca Avino, Annamaria Borghi, Sara Contardi, Andrea Zini, Carlo Ferrarese, Simone Beretta

“…The most frequent neurological diagnosis in cases were stroke (60.4%), multiple sclerosis (11.3%) and seizures (6.4%). The proportion of vaccinated participants was 72.1% among cases and 79.6% among controls. …”
Get full text